Ares, a private equity group, agreed to invest in The Lockwood Group, a firm that communicates clinical and therapeutic advances to every type of medical expert, healthcare practitioner, and decision maker. Financial terms were not disclosed. "We are excited to find in Ares a partner that appreciates our differentiated culture, deep scientific expertise, and close-knit community of teammates. Ares brings a wealth of resources and experience that we believe will help Lockwood accelerate growth by investing in our people, customers, and capabilities. Our team is energized by the opportunity ahead of us," Matthew Schecter, Lockwood President and CEO.